ARTICLE | Clinical News
Conatus sinks after NASH therapy misses fibrosis endpoint
March 21, 2019 11:27 PM UTC
Conatus lost $1.49 (51%) to $1.42 in after-hours trading Thursday after reporting that emricasan missed the primary endpoint in the Phase IIb ENCORE-NF to treat non-alcoholic steatohepatitis fibrosis.
ENCORE-NF's primary endpoint evaluated the proportion of patients who achieved at least a 1-stage improvement in fibrosis with no worsening of steatohepatitis at week 72 vs. placebo...
BCIQ Target Profiles